Nov 14, 2024
Positive Data from Phase II Trial in Soft Tissue Sarcoma Presented at CTOS 2024 Annual Meeting
Oct 28, 2024
Immutep Quarterly Activities Report Q1 FY25
Immutep to Present New Phase IIb Data in PD-L1 Negative (CPS <1) Head and Neck Cancer at ESMO Immuno-Oncology 2024
Oct 17, 2024
Immutep Announces First-in-Human Phase I Study of IMP761 Progresses to Dose Escalation Portion of Trial
Oct 10, 2024
Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit
